Dry Age-related Macular Degeneration (Dry AMD) Market Insights and Forecast 2024-2034: Emerging Therapies, Trends, and Key Players

The potential therapies that can mark a significant change in the upcoming forecast period include AVD-104, Tinlarebant (LBS-008), Gildeuretinol (ALK-001), Elamipretide, ANX007, Danicopan (ALXN2040), IONIS-FB-LRx (RG6299), JNJ-1887, CPCB-RPE1, OpRegen, and others.
In 2023, in the 7MM the total market size of dry AMD was ~ USD 1,300 million.

Dry Age-related Macular Degeneration (Dry AMD) [https://www.delveinsight.com/sample-request/dry-age-macular-degeneration-market?utm_source=linkedin&utm_medium=promotion&utm_campaign=kpr] is a common eye disorder among people over 50. It is a chronic disease that causes deterioration of the macula, the central part of the retina responsible for clear vision in your direct line of sight. Unlike the wet form of AMD, which involves abnormal blood vessel growth, dry AMD is characterized by the thinning of macular tissues and the accumulation of drusen, which are yellow deposits

Dry Age-related Macular Degeneration Market [https://www.delveinsight.com/report-store/dry-age-macular-degeneration-market?utm_source=linkedin&utm_medium=promotion&utm_campaign=kpr] Insights:

Geographic atrophy (GA), the advanced stage of dry AMD, has become a significant research focus. Current investigations primarily target complement inhibitors of C3 and C5, crucial factors in triggering inflammation and subsequent cell death within the eye. Extensive studies by the National Eye Institute and other esteemed researchers globally have revealed that an overactive complement system likely plays a central role in the genesis of dry AMD and its progression to GA.

Enhancing our understanding of the pathophysiology of GA resulting from dry AMD can benefit patients, optometrists, and ophthalmologists alike. This improved understanding could lead to more accurate identification and diagnosis, potentially reducing the disease burden and extending patients' visual function over time.

Research and development in intermediate AMD have increasingly focused on dry AMD, exemplified by Stealth Biotherapeutics redirecting its efforts towards this area. For instance, Elamipretide, a mitochondria-targeting antioxidant, has progressed to Phase II trials for dry AMD following promising outcomes in Phase I trials for intermediate AMD.

Immune response-targeting agents have become the most advanced area of clinical research for GA, marking a significant milestone as the first and only drug class to enter the market. FDA approvals of IZERVAY (avacincaptad pegol) and SYFOVRE (pegcetacoplan) represent groundbreaking developments. Both medications have demonstrated their ability to effectively slow the progression of GA, thereby mitigating vision loss. These approvals signal a transformative shift in clinical practice, research priorities, investment decisions, and healthcare planning. While these breakthrough medications offer hope for individuals with late-stage dry AMD, they signify just the initial steps in advancing treatment options for GA.

Numerous therapies are currently under investigation to slow the progression of GA and maintain macular function in patients with dry AMD. These potential treatments in clinical trials, focused on disease prevention and halting progression, include ALK-001, Elamipretide, Risuteganib, EG-301, ANX 007, IONIS-FB-LRx, NGM 621, and JNJ-1887 (AAVCAGsCD59), among others.

*
The total market size in the US for dry AMD was estimated to be ~USD 800 million in 2023, which is expected to grow during the forecast period (2024-2034).

*
The total market size in EU4 and the UK for dry AMD was estimated to be nearly USD 300 million in 2023, which is expected to grow during the forecast period.

[https://www.delveinsight.com/report-store/dry-age-macular-degeneration-market?utm_source=linkedin&utm_medium=promotion&utm_campaign=kpr] In The Market:

Key Dry Age-related Macular Degeneration companies in the market include Alkeus Pharmaceuticals, Belite Bio, Aviceda Therapeutics, Johnson & Johnson Innovative Medicine, Allegro Ophthalmics, Lineage Cell Therapeutics (CellCure Neurosciences), Roche, Cognition Therapeutics, Stealth BioTherapeutics, Evergreen Therapeutics, Annexon Biosciences, NGM Biopharmaceuticals, AstraZeneca, Alexion Pharmaceuticals, Ionis Pharmaceuticals, Novartis, Regenerative Patch Technologies, and others.

Explore the latest insights on Dry Age-related Macular Degeneration Market. Stay informed for better treatment options. Visit now @ https://www.delveinsight.com/report-store/dry-age-macular-degeneration-market [https://www.delveinsight.com/report-store/dry-age-macular-degeneration-market?utm_source=linkedin&utm_medium=promotion&utm_campaign=kpr]

Dry Age-related Macular Degeneration Epidemiology:

The epidemiology chapter on Dry AMD in the report offers both historical and forecasted data. It is segmented into several categories: total prevalent cases of AMD, stage-specific prevalent cases of AMD, total prevalent cases of geographic atrophy, total prevalent cases of dry AMD, and total diagnosed prevalent cases of dry AMD. Additionally, it includes age-specific cases of early and intermediate AMD, age-specific cases of geographic atrophy, and geographic atrophy cases by visual impairment. This data covers the 7MM market, which includes the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan, spanning from 2020 to 2034.

*
The total prevalent cases of AMD in the 7MM was nearly 68,347,900 in 2023.

*
Among the 7MM, the US accounted for the highest prevalent cases of dry AMD in 2023, with around 20,970,000 cases; these cases are expected to increase during the forecast period.

Dry Age-related Macular Degeneration Market Dynamics

The dynamics of the dry AMD market are expected to change in the coming years. The dry AMD market has a miscellaneous pipeline, including peptide derivatives, antibodies, antisense oligonucleotides, stem cell therapy, and gene therapy, which work on different mechanisms such as C1q, C3, and C5 Inhibitors, cell replacements, HtrA Serine Peptidase 1 inhibitors, and others. This dry AMD market remains untapped, with a large and increasing patient pool.

Furthermore, many potential therapies are being investigated for the treatment of dry AMD, and it is safe to predict that the treatment space will significantly impact the dry AMD market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate are expected to drive the growth of the dry AMD market in the 7MM.

As new drugs are expected to receive approval from regulators after 2025-2027, it will be interesting to follow how the landscape of Dry AMD, particularly geographic atrophy, changes. At this point, no medication is now on the cusp of approval and poses an immediate threat to SYFOVRE or IZERVAY.

However several factors may impede the growth of the dry AMD market. There is a lack of validated endpoint which may hamper the advancement of the therapies and to show their clinical benefits; most of the emerging therapies are targeting geographic atrophy, and this might impact the uptake of emerging drugs owing to anticipated intense competition in the same segment, while emerging gene therapies and stem cell therapies for dry AMD may face hurdles in access and reimbursement due to its anticipated high cost.

Moreover, dry AMD treatment poses a significant economic burden and disrupts patients' overall well-being and QOL. Furthermore, the dry AMD market growth may be offset by failures and discontinuation of emerging therapies, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the dry AMD market growth.

Explore the detailed Market Insight report on Dry Age-related Macular Degeneration for valuable insights to make informed decisions @ https://www.delveinsight.com/sample-request/dry-age-macular-degeneration-market [https://www.delveinsight.com/sample-request/dry-age-macular-degeneration-market?utm_source=linkedin&utm_medium=promotion&utm_campaign=kpr]

Table of Contents

1. Report Introduction

2. Executive Summary

3. SWOT analysis

4. Dry Age-related Macular Degeneration (Dry AMD) Patient Share (%) Overview at a Glance

5. Dry Age-related Macular Degeneration (Dry AMD) Market Overview at a Glance

6. Dry Age-related Macular Degeneration (Dry AMD) Disease Background and Overview

7. Dry Age-related Macular Degeneration (Dry AMD) Epidemiology and Patient Population

8. Country-Specific Patient Population of Dry Age-related Macular Degeneration (Dry AMD)

9. Dry Age-related Macular Degeneration (Dry AMD) Current Treatment and Medical Practices

10. Unmet Needs

11. Dry Age-related Macular Degeneration (Dry AMD) Emerging Therapies

12. Dry Age-related Macular Degeneration (Dry AMD) Market Outlook

13. Country-Wise Dry Age-related Macular Degeneration (Dry AMD) Market Analysis (2020-2034)

14. Market Access and Reimbursement of Therapies

15. Market drivers

16. Market barriers

17. Appendix

18. Dry Age-related Macular Degeneration (Dry AMD) Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=dry-agerelated-macular-degeneration-dry-amd-market-insights-and-forecast-20242034-emerging-therapies-trends-and-key-players]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.